Chief Scientific Officer · Cerevel Therapeutics Holdings, Inc. (CERE)

John Renger

A named executive officer of Cerevel Therapeutics in every fiscal year CompBrief holds from FY2019 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$4,779,729

Salary $482,052Stock awards $0

FY2021: $3,093,750

3rd of 5 named executive officers at Cerevel Therapeutics by FY2022 total.

5 named officers on file for Cerevel Therapeutics, FY2022

John Renger’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • CERE’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Cerevel Therapeutics’s whole pay program stands against its peers

  • Cerevel Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CERE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get John Renger’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

John Renger compensation by year

Cerevel Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Cerevel Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022
Salary$330,411$450,000$463,276$482,052
Bonus$130,000$0$0$0
Stock awards$0$0$0$0
Option awards$1,489,792$900,000$2,400,000$3,999,979
Non-equity incentive$151,989$266,400$213,074$279,398
Pension and deferred compensation$0$0$0$0
All other$26,716$228,675$17,400$18,300
Total$2,128,908$1,845,075$3,093,750$4,779,729

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cerevel Therapeutics Holdings, Inc. DEF 14A filed April 28, 2023, accession 0000950170-23-015766, and prior-year filings.

How this page was built: the Cerevel Therapeutics Holdings, Inc. filed document, accession 0000950170-23-015766. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2023.

$2.1M
$1.8M
$3.1M
$4.8M
FY19
FY20
FY21
FY22
SalaryBonusNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
Option13,358—$10.28
Option134,160—$12.70
Option168,856—$30.36
Option58,901—$9.88
Option40,073—$3.50

Per the Outstanding Equity Awards at Fiscal Year-End table in Cerevel Therapeutics Holdings, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

8 Form 4 lines since the FY2022 proxy (filed April 28, 2023)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2024-08-01Disposition to the issuer derivative—87,573$0.000
2024-08-01Disposition to the issuer—6,370—0
2024-08-01Disposition to the issuer derivative—778,418—0
2024-08-01Disposition to the issuer derivative—15,061$0.000
2024-02-07Sale—2,161$41.546,370
2024-02-06Exercise or conversion—5,020—8,531
2024-02-06Exercise or conversion derivative—5,020$0.0015,061
2024-01-19Grant or award derivative—87,573$0.0087,573

The 8 most recent of 8 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Cerevel Therapeutics’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
N. Anthony ColesChief Executive Officer and Chairperson of the Board of Directors$11,225,426
Raymond SanchezChief Medical Officer$4,805,110
John Renger · this pageChief Scientific Officer$4,779,729
Abraham CeesayPresident$3,676,491
Mark BodenraderInterim Chief Financial Officer; Senior Vice President, Finance and Chief Accounting Officer$1,583,640

The full Cerevel Therapeutics compensation record

free company brief

This page is one person within Cerevel Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Cerevel Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cerevel Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

John Renger's compensation dossier · One-time report. No refunds.